InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS
Start Date
1/1/2025
Completion Date
4/1/2026
Summary
The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.
Detailed Description
This single-dose, double-blind, random allocation, sham-control, clinical trial will recruit spontaneously breathing newborns with RDS stable on non-invasive nasal respiratory support. Enrolled clinical study subjects will be randomly allocated to receive respiratory air with Infasurf® (Intervention Arm) or respiratory air alone (Sham Control Arm) through the InfasurfAero™. The objectives of this clinical study are to i) assess the effectiveness of a single dose of Infasurf administered through the InfasurfAero in preventing CPAP failure, and ii) assess the safety of Infasurf administered through the InfasurfAero. Subjects will be enrolled at one of 10+ sites. 7 sites are currently recruited.
Eligibility Criteria
Age Range: No minimum to No maximum
Interventions
Infasurf Aero™
Conditions
Locations
St. Josephs Hospital and Medical Center
Phoenix, Arizona 85013
United States
Phoenix Children's
Phoenix, Arizona 85016
United States
Sharp Mary Birch Hospital for Women & Newborns
San Diego, California 92123
United States
University of Florida -Jacksonville
Jacksonville, Florida 32209
United States
Kapi'olani Medical Center for Women & Children
Honolulu, Hawaii 96826
United States
Jersey Shore University Medical Center
Neptune City, New Jersey 07753
United States
Sisters of Charity Hospital
Buffalo, New York 14214
United States
Western TN- Jackson-Madison County General Hospital
Jackson, Tennessee 38301
United States
Utah Valley Hospital
Provo, Utah 84604
United States
Unity Point Meriter
Madison, Wisconsin 53715
United States